Miniatura

Fitxers

249002.pdf (1.71 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-02-21

Llicència de publicació

cc by (c) Rodríguez Espinosa, Diana et al., 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/213982

Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1007/s40620-022-01257-5

Resum

Introduction: Given the increased COVID-19 observed in kidney transplant recipients (KTRs) and haemodialysis patients, several studies have tried to establish the efficacy of mRNA vaccines in these populations by evaluating their humoral and cellular responses. However, there is currently no information on clinical protection (deaths and hospitalizations), a gap that this study aims to fill. Methods: Observational prospective study involving 1,336 KTRs and haemodialysis patients from three dialysis units affiliated to Hospital Clínic of Barcelona, Spain, vaccinated with two doses of mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 mRNA vaccines. The outcomes measured were SARS-CoV-2 infection diagnosed by a positive RT-PCR fourteen days after the second vaccine dose, hospital admissions derived from infection, and a severe COVID-19 composite outcome, defined as either ICU admission, invasive and non-invasive mechanical ventilation, or death. Results: Six per cent (18/302) of patients on haemodialysis were infected, of whom four required hospital admission (1.3%), only one (0.3%) had severe COVID-19, and none of them died. In contrast, 4.3% (44/1034) of KTRs were infected, and presented more hospital admissions (26 patients, 2.5%), severe COVID-19 (11 patients, 1.1%) or death (4 patients, 0.4%). KTRs had a significantly higher risk of hospital admission than HD patients, and this risk increased with age and male sex (HR 3.37 and 4.74, respectively). Conclusions: The study highlights the need for booster doses in KTRs. In contrast, the haemodialysis population appears to have an adequate clinical response to vaccination, at least up to four months from its administration.

Matèries

COVID-19, Trasplantament renal, Hemodiàlisi, Vacunació, SARS-CoV-2

Matèries (anglès)

COVID-19, Kidney transplantation, Hemodialysis, Vaccination, SARS-CoV-2

Citació

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

RODRÍGUEZ ESPINOSA, Diana, MONTAGUD MARRAHI, Enrique, CACHO, Judit, ARANA, Carolt, TAURIZANO, Natalia, HERMIDA, Evelyn, DEL RISCO ZEVALLOS, Jimena, CASALS URQUIZA, Joaquim, ROSARIO, Anney, CUADRADO PAYÁN, Elena, MOLINA ANDÚJAR, Alícia, RODRÍGUEZ, Néstor, VILELLA I MORATÓ, Anna, BODRO, Marta, VENTURA AGUIAR, Pedro, REVUELTA, Ignacio, COFÁN PUJOL, Federico, POCH, Esteban, OPPENHEIMER SALINAS, Federico, VERA, Manel, RODAS, Lida m., CASES, Aleix, BAYÉS, Beatriu, DIEKMANN, Fritz, MADUELL, Francisco, BROSETA, José jesús, CUCCHIARI, David. Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients. _Journal of Nephrology_. 2022. Vol. 35, núm. 3, pàgs. 769-778. [consulta: 21 de gener de 2026]. ISSN: 1121-8428. [Disponible a: https://hdl.handle.net/2445/213982]

Exportar metadades

JSON - METS

Compartir registre